Immuneering Corporation

NASDAQ (USD): Immuneering Corporation (IMRX)

Last Price

1.83

Today's Change

-0.07 (3.68%)

Day's Change

1.80 - 1.90

Trading Volume

227,326

Overview

Market Cap

54 Million

Shares Outstanding

29 Million

Avg Volume

5,536,329

Avg Price (50 Days)

2.12

Avg Price (200 Days)

2.44

PE Ratio

-0.96

EPS

-1.90

Earnings Announcement

11-Nov-2024

Previous Close

1.90

Open

1.90

Day's Range

1.8 - 1.9

Year Range

1.0 - 8.89

Trading Volume

227,326

Price Change Highlight

1 Day Change

-3.68%

5 Day Change

-4.69%

1 Month Change

-16.44%

3 Month Change

60.53%

6 Month Change

26.21%

Ytd Change

-75.00%

1 Year Change

-62.19%

3 Year Change

-93.43%

5 Year Change

-89.60%

10 Year Change

-89.60%

Max Change

-89.60%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment